share_log
Reuters ·  Mar 27 15:00
Merck: Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Shows Noninferior Pharmacokinetics Vs IV Keytruda in 3475a-D77 Trial
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 257

Recommended

Write a comment